Alnylam Pharmaceuticals, Inc. (ALNY) Price Target Raised to $50.00 at Morgan Stanley

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) had its price target boosted by research analysts at Morgan Stanley from $46.00 to $50.00 in a research report issued to clients and investors on Thursday. The brokerage presently has an “equal weight” rating on the biopharmaceutical company’s stock. Morgan Stanley’s target price indicates a potential downside of 37.91% from the stock’s previous close.

A number of other brokerages have also recently issued reports on ALNY. Cowen and Company reiterated a “buy” rating and issued a $100.00 price target on shares of Alnylam Pharmaceuticals in a research note on Tuesday, July 11th. Vetr cut shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $71.50 price target on the stock. in a research note on Monday, May 15th. Piper Jaffray Companies set a $118.00 price target on shares of Alnylam Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, May 15th. Barclays PLC upped their price target on shares of Alnylam Pharmaceuticals from $50.00 to $70.00 and gave the stock an “equal weight” rating in a research note on Thursday. Finally, Credit Suisse Group upped their price target on shares of Alnylam Pharmaceuticals from $90.00 to $96.00 and gave the stock an “outperform” rating in a research note on Tuesday, June 27th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. Alnylam Pharmaceuticals has an average rating of “Buy” and a consensus target price of $81.12.

Alnylam Pharmaceuticals (NASDAQ ALNY) traded down 6.01% on Thursday, hitting $75.68. 1,345,917 shares of the company’s stock were exchanged. The firm has a 50 day moving average price of $81.35 and a 200-day moving average price of $61.53. Alnylam Pharmaceuticals has a 52-week low of $31.38 and a 52-week high of $86.92. The stock’s market cap is $6.52 billion.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($1.34) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.22) by $0.12. The firm had revenue of $15.93 million during the quarter, compared to the consensus estimate of $23.86 million. Alnylam Pharmaceuticals had a negative return on equity of 42.90% and a negative net margin of 705.11%. The business’s revenue for the quarter was up 82.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($1.05) EPS. Analysts predict that Alnylam Pharmaceuticals will post ($5.21) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This report was originally reported by Ticker Report and is the property of of Ticker Report. If you are viewing this report on another site, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this report can be viewed at https://www.tickerreport.com/banking-finance/2798321/alnylam-pharmaceuticals-inc-alny-price-target-raised-to-50-00-at-morgan-stanley.html.

In other Alnylam Pharmaceuticals news, major shareholder Sanofi purchased 297,501 shares of Alnylam Pharmaceuticals stock in a transaction dated Wednesday, May 31st. The stock was purchased at an average price of $71.87 per share, with a total value of $21,381,396.87. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, VP Michael Mason sold 9,375 shares of the company’s stock in a transaction dated Tuesday, May 16th. The shares were sold at an average price of $70.00, for a total transaction of $656,250.00. Following the sale, the vice president now directly owns 5,625 shares of the company’s stock, valued at approximately $393,750. The disclosure for this sale can be found here. Insiders have sold a total of 64,125 shares of company stock valued at $4,325,000 in the last ninety days. Insiders own 4.30% of the company’s stock.

Several large investors have recently added to or reduced their stakes in ALNY. BlackRock Inc. raised its stake in Alnylam Pharmaceuticals by 34,755.2% in the first quarter. BlackRock Inc. now owns 4,746,234 shares of the biopharmaceutical company’s stock valued at $243,242,000 after buying an additional 4,732,617 shares during the last quarter. Perceptive Advisors LLC raised its stake in Alnylam Pharmaceuticals by 831.4% in the first quarter. Perceptive Advisors LLC now owns 1,103,475 shares of the biopharmaceutical company’s stock valued at $56,553,000 after buying an additional 985,000 shares during the last quarter. Rockefeller Financial Services Inc. raised its stake in Alnylam Pharmaceuticals by 4,724.4% in the first quarter. Rockefeller Financial Services Inc. now owns 506,223 shares of the biopharmaceutical company’s stock valued at $25,944,000 after buying an additional 495,730 shares during the last quarter. Blue Ridge Capital L.L.C. raised its stake in Alnylam Pharmaceuticals by 20.5% in the first quarter. Blue Ridge Capital L.L.C. now owns 1,590,000 shares of the biopharmaceutical company’s stock valued at $81,488,000 after buying an additional 270,000 shares during the last quarter. Finally, Pictet Asset Management Ltd. raised its stake in Alnylam Pharmaceuticals by 72.2% in the first quarter. Pictet Asset Management Ltd. now owns 563,771 shares of the biopharmaceutical company’s stock valued at $28,893,000 after buying an additional 236,379 shares during the last quarter. 88.96% of the stock is owned by hedge funds and other institutional investors.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.